AstraZeneca RSG Programme Targets $1.5B in Annualized Benefits
AstraZeneca expects the RSG programme to incur up to $2.0 billion in one-time restructuring costs and deliver $1.5 billion in annualized pre-tax run-rate benefits.
AstraZeneca expects the RSG programme to incur up to $2.0 billion in one-time restructuring costs and deliver $1.5 billion in annualized pre-tax run-rate benefits.